Photothermal therapy agent NIR dye-conjugated maltodextrin for anticancer
발표자
()
초록
내용
Photodynamic therapy (PDT) is one of the anticancer treatment methods that using laser and photosensitizers. In PDT, it is critical to deliver photosensitizers to tumors specifically. In this study, we hypothesized that IR820-conjugated maltodextrin (MDir) has ability of preferentially uptake to cancer cells and serve as photothermal agents. Maltodextrin is selectively uptake to cancer cell depending on the presence or absence of maltodextrin transporters. IR820 is a clinically used imaging agent and has potential as a photosensitizer for PDT. In the studies of a xenograft mouse model, These newly conjugated MDir preferentially accumulated in tumors and induced almost complete thermal ablation of tumor NIR laser irradiation. Based on its cancer targeting ability, photothermal conversion efficiency and excellent biocompatibility, we anticipate that MDir could serve as great translational potential as fluorescence-guided photothermal agent for cancer treatment.